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Evidence is conflicting regarding the clinical benefits of selecting P2Y12 inhibitors based on
platelet function testing (PFT). Between March 1, 2013 and March 1, 2014, we collected
clinical characteristics and platelet function data in a nationwide acute myocardial infarc-
tion (AMI) registry from 15 interventional cardiology centers in Hungary. The risk of all-
cause mortality at 1 year were compared after propensity score (PS) matching between patients
receiving PFT-guided and unguided P2Y12-inhibitor therapies. High platelet reactivity on
clopidogrel (HPRoC) was uniformly defined with the Multiplate assay. A total of 5,583 pa-
tients with AMI and coronary intervention were registered. After exclusion of cases with
contraindication to prasugrel, propensity matching resulted in a sample of 2,104 patients
with well-adjusted characteristics. Clopidogrel was the dominant P2Y12 inhibitor in both
groups (unguided: 96% vs PFT guided: 85%, p <0.001). In the PFT-guided group, 19% of
patients had HPRoC and 77% of them were switched to prasugrel. According to the ad-
justed analysis, all-cause mortality at 1 year was significantly lower in the PFT-guided compared
with the unguided group (hazard ratio 0.57 [95% confidence interval 0.43 to 0.77], p <0.001).
Although prasugrel treatment was not associated with lower all-cause mortality in the overall
cohort, patients with HPRoC who switched to prasugrel had significantly lower mortality
when compared with those continuing clopidogrel (hazard ratio 0.33 [95% confidence in-
terval 0.12 to 0.92], p <0.05). In conclusion, in patients with AMI, PFT-guided treatment
with a high rate of switchover to prasugrel was associated with a lower risk of mortality.
Prasugrel was a predictor of lower mortality in patients with HPRoC but not in the overall
cohort of AMI. © 2018 The Author(s). Published by Elsevier Inc. This is an open access
article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
(Am J Cardiol 2018;121:1129–1137)
Inhibition of platelet aggregation is one of the major thera-
peutic targets in patients with an acute myocardial infarction
(AMI). Among platelet P2Y12-receptor inhibitors, prasugrel
and ticagrelor are the preferred choices for patients with AMI.1,2
Due to contraindications, financial restrictions, and regula-
tory reasons, the availability of prasugrel and ticagrelor is not
uniform across countries, whereas the use of clopidogrel and
switching between P2Y12 inhibitors is frequent.3–5 High plate-
let reactivity on clopidogrel (HPRoC) is an independent
predictor of stent thrombosis and myocardial infarction.6–8
However, current guidelines discourage the routine use of plate-
let function testing (PFT) due to lack of evidence on the ability
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of PFT-based P2Y12 therapy to improve outcomes.1,2 Local
reimbursement regulations in Hungary mandate PFT on
clopidogrel, and prasugrel is reimbursed for patients with
HPRoC. This policy resulted in a high penetration of PFT
across invasive centers. We sought to evaluate the clinical
impact of PFT guidance based on a nationwide registry of
patients with AMI who were treated with coronary intervention.
Methods
The Hungarian Myocardial Infarction Registry is a pro-
spective, Internet-based registry collecting clinical data on
consecutive patients treated for an event of AMI in Hungary,
a country with 9.8 million residents. At the time of the con-
duction of the present study, the registry operated on a
voluntary basis, capturing 51% of AMI cases treated
countrywide.9–11 The protocol of the study is in accordance
with the Declaration of Helsinki and was reviewed by the
ethical board. All patients recorded in the registry gave written
informed consent.
Between March 1, 2013 and March 1, 2014, all patients
with AMI (both with ST segment elevation and without) were
eligible for enrollment if intervention was performed suc-
cessfully with stent implantation and there was no
contraindication to treatment with a P2Y12 inhibitor for 1 year.
Data of patients treated in 15 centers of invasive cardiology
collaborating with providing and monitoring platelet func-
tion data were analyzed.
Patients with an indication of chronic oral anticoagula-
tion, with a history of stroke or transient ischemic attack, who
are aged older than 75 years, who weigh less than 60 kg, or
who have had an administration of P2Y12 inhibitors other than
clopidogrel or prasugrel before or during intervention were
excluded. Thienopyridins were supplemented with low-
dose aspirin, typically 100 mg with an optional loading dose
of 300 to 500 mg. The use of perioperative anticoagulation
and the administration of platelet IIb/IIIa inhibitors were
allowed according to the local protocols.
Generally, P2Y12-inhibitor treatment before intervention
comprised clopidogrel, usually given in a loading dose of
600 mg but left to the decision of the treating physicians. After
intervention, both prasugrel and clopidogrel were available
for long-term treatment. However, although clopidogrel use
was not restricted by any reimbursement rule, prasugrel was
reimbursed at 70% only if PFT results confirmed HPRoC. Im-
portantly, it was left to the discretion of the treating physicians
whether to perform PFT and make the choice based on PFT
(PFT-guided group) or make a clinical decision without PFT
(unguided group).
All participating centers used a homogeneous method for
PFT, which was the Multiplate analyzer (Roche Diagnos-
tics GmbH, Rotkreuz, Switzerland). PFT was performed at
least 6 hours after the intervention or at least 24 hours after
platelet IIb/IIIa inhibitor treatment cessation.12 HPRoC was
defined as an adenosine diphosphate test level >46 U.12 The
choice of P2Y12 inhibitor in patients with HPRoC was also
left to the treating physician: either switch to prasugrel, or
high (150 mg/day) or conventional doses (75 mg) of
clopidogrel were allowed.
The primary efficacy end point was all-cause mortality
within 1 year after the index procedure. Secondary end points
included the composite of cardiovascular death, recurrent myo-
cardial infarction, and stroke as well as transfusion and the
individual elements of the composite end point. Overall mor-
tality was obtained from the patient vital status in the database
of the Hungarian Central Statistical Office and the National
Health Insurance Fund, including the date and the cause of
death. In patients who died, the cause of death was assessed
by qualifying deaths related to infection, malignancy, and
trauma as noncardiovascular. Data related to recurrent hos-
pitalization for AMI, for stroke, as well as for bleeding event
leading to transfusion were extracted from the database of
the National Health Insurance Fund.
Variables are presented as means ± SD or as frequencies
and percentages. Unpaired t tests were used for compari-
sons of continuous variables between groups. Categorical
variables were compared using chi-square or Fisher’s exact
test as appropriate. As eligible patients were not randomly
assigned to PFT-guided or unguided treatments, we in-
tended to balance the groups to reduce potential bias associated
with treatment selection. For this aim we built a propensity
score (PS)–matched cohort with comparable chance for either
strategy by adjusting for differences in baseline characteris-
tics. PS was computed by using a logistic regression model
for PFT-guided versus unguided groups. Patient character-
istics at presentation and clinical factors from the medical
history with potential influence on the decision regarding PFT
(listed in Table 1) were used as predictors in calculating PS.
In the PS-matching procedure, we first randomly selected a
patient in the unguided group and matched him or her with
a patient from the PFT-guided group with the closest esti-
mated PS value. We performed a 1-to-1 matched analysis
without replacement with a match tolerance of <0.01. Un-
adjusted hazard ratios (HRs) and 95% confidence intervals
(CIs) were determined in univariate Cox proportional models,
and then a multivariable Cox proportional hazards model was
used to determine independent predictors of all-cause mor-
tality. As a sensitivity exercise, PFT-guided and unguided
patients were compared also in the PS-unmatched study popu-
lation with Cox regression analyses. All reported p values are
2-sided, and p values of <0.05 were considered to indicate
statistical significance. This analysis was conducted using the
SPSS 22 statistical package.
Results
From March 1, 2013 to March 1, 2014, data of 6,795 pa-
tients hospitalized in the participating centers for an event of
AMI were entered in the registry. Of these, 5,583 patients
(82.2%) were treated with coronary intervention and stenting.
In 3,715 cases (66.5%), long-term P2Y12-inhibitor treat-
ment was chosen based on PFT results (PFT-guided group),
whereas PFT was not performed in 1,868 cases (unguided
group 33.5%). After excluding 29% of patients with abso-
lute or relative contraindications to prasugrel, an unmatched
patient pool of 3,974 cases was obtained (Figure 1). As ex-
pected, there were numerous differences in baseline
characteristics between the groups. To adjust for these dif-
ferences, PS matching was performed that resulted in a
matched population of 2,104 patients (Table 1).
Among the 2,901 subjects of the PFT-guided group, 554
(19%) had HPRoC. Seventy percent of them were switched
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to prasugrel, whereas 30% continued clopidogrel (14% high-
dose and 16% standard-dose clopidogrel). In patients without
HPRoC (no HPRoC group), use of prasugrel was low (2%),
resulting in an overall high proportion of patients continu-
ing clopidogrel based on PFT guidance. Among unguided
patients, prasugrel was prescribed only in 4%, whereas low-
dose clopidogrel was quite frequent (74%). Treatment
allocation patterns in the PS-matched cohort remained similar
with 77% switchover to prasugrel in patients with HPRoC
(Figure 2).
During the follow-up period, 200 patients died from the
PS-matched cohort, resulting in a 1-year all-cause mortality
rate of 9.5%, in this unselected, high-risk cohort. PFT-
guided subjects had a highly significant, 43% lower hazard
for all-cause mortality compared with the unguided group.
Similar to this, cardiovascular mortality was also reduced by
39% (Figure 3 and Table 2). In the unmatched total cohort
including 3,974 patients, similar results were observed for all-
cause and cardiovascular mortality without a significant
difference in the risk of stroke or repeat myocardial infarc-
tion (Table 2). As the use of prasugrel was higher in the PFT-
guided than in the unguided group (16% vs 4%, p <0.001),
its potential impact on survival was calculated in the overall
analysis populations. Prasugrel treatment, however, was not
associated with lower risk of mortality in the PS-matched (HR
0.65 [0.38 to 1.11], p = 0.116) or in the unmatched cohorts
(HR 0.75 [0.51 to 1.11], p = 0.145).
As a prespecified analysis, the clinical impact of prasugrel
and clopidogrel were tested on all-cause mortality within sub-
groups of PFT-guided and unguided therapy, and across
HPRoC groups. Within the PFT-guided group of PS-matched
patients, clopidogrel use was associated with significantly
worse survival compared with prasugrel in case of HPRoC.
Among clopidogrel-treated patients with HPRoC, high-
dose clopidogrel was associated with a numerically lower risk
of mortality than standard-dose clopidogrel (8.7% vs 21.7%),
Table 1
Characteristics of the patient population before and after propensity score matching
Clinical characteristics Entire cohort (n = 3974) Propensity matched cohort (n = 2104)
PFT-guided
(n = 2901)
Unguided treatment
(n = 1073)
p value PFT-guided
(n = 1052)
Unguided treatment
(n = 1052)
p value
Age, (years) * 58.9 ± 9.6 60.5 ± 9.2 <0.001 60.5 ± 9.0 60.5 ± 9.1 0.926
Men * 69.3 % 65.7 % 0.035 65.3 % 66.1 % 0.748
Medical history
Hypertension 64.6 % 71.2 % <0.001 68.41 % 70.6 % 0.297
Diabetes mellitus 24.8 % 29.2 % 0.006 27.8 % 28.4 % 0.734
- insulin 1.6 % 1.6 % 1.000 1.0 % 1.5 % 0.324
Hyperlipidemia * 11.1 % 5.1 % <0.001 3.7 % 5.2 % 0.113
Smoker
(current/past/never)
35.2/1.6/63.3 % 36.1/2.1/61.9 % 0.458 36.2/1.8/62.0 % 36.2/1.9/61.8 % 0.950
Prior myocardial infarction 15.8 % 27.4 % <0.001 26.6 % 26.0 % 0.771
Prior coronary intervention* 4.6 % 7.3 % 0.001 7.1 % 7.4 % 0.867
Prior of coronary bypass
operation *
1.8 % 1.0 % 0.113 0.8 % 1.0 % 0.646
Peripheral artery disease * 5.3 % 11.6 % <0.001 10.2 % 10.4 % 0.943
Presentation
ST segment elevation
myocardial infarction *
64.1 % 51.0 % <0.001 55.1 % 51.7 % 0.126
Culprit artery (LM/LAD/
Cx/RCA/VSG
2.8/46.7/23.0/35.8/1.2 % 3.3/44.1/25.9/35.8/1.1 % 0.3461 2.9/46.7/24.4/34.3/1.2 % 2.9/44.2/25.5/36.0/1.0 % 0.734
Heart rate (bpm) 79.8 ± 17.1 80.6 ± 18.1 0.236 81.4 ± 18.0 80.5 ± 18.1 0.250
Systolic blood pressure
(mm Hg)*
137.9 ± 24.2 136.6 ± 25.7 0.191 138.6 ± 24.8 136.5 ± 25.7 0.054
Diastolic blood pressure
(mm Hg)*
70.0 ± 24.7 68.7 ± 25.0 0.168 67.9 ± 26.1 68.8 ± 25.1 0.440
Adenosin diphosphate
reactivity
32.5 ± 19.5 - NA 32.5 ± 19.9 - NA
High platelet reactivity 19.1 % - NA 18.6 % - NA
Medications
Clopidogrel 75 mg daily 50.6 % 74.3 % <0.001 43.6 % 74.2 % <0.001
Clopidogrel 150 mg daily 34.4 % 21.6 % 40.2 % 21.8 %
Prasugrel 15.0 % 4.1 % 16.2 % 4.0 %
Aspirin 71.1 % 81.0 % <0.001 80.9 % 79 % 0.547
ß-blocker 84.1 % 90.6 % <0.001 88.5 % 90.4 % 0.176
Statin 81.0 % 91.8 % <0.001 91.6 % 91.7 % 0.579
Data are presented as percentages or as mean ± standard deviation. Asterisk marks parameters associated to the invasive therapy in binary logistic model.
* p value < 0.1.
LM = left main coronary artery; LAD = left anterior descending artery; Cx = left circumflex artery; RCA = right coronary artery; SVG = saphenous vein
graft.
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but this difference did not reach the level of statistical sig-
nificance (HR 0.37 [95% CI 0.07 to 1.88], p = 0.228). In the
unguided group and in patients without HPRoC of the guided
cohort, prasugrel versus clopidogrel therapy was not a sig-
nificant predictor of survival (Figures 4 and 5).
To separate and analyze the potential role of PFT on mor-
tality independently from other potentially relevant
determinants, univariate and multivariate models were gen-
erated. In the multivariate model, beyond known risk factors
including age, smoking, history of peripheral artery disease,
hypertension, diabetes, high heart rate or low arterial pres-
sures at presentation, and left main coronary involvement, PFT
guidance remained a significant, independent predictor of lower
all-cause mortality, whereas prasugrel therapy was not asso-
ciated with an improved overall survival (Table 3).
Discussion
Our analysis of a large, prospective, unselected database
of patients treated with coronary intervention due to an event
of AMI showed improved survival in patients with PFT-
guided antiplatelet treatment compared with an unguided
strategy. Explorative analyses demonstrated that the results
of PFT had an important impact on the selected P2Y12-inhibitor
therapy as patients without PFT guidance were more fre-
quently kept on clopidogrel, whereas those in the PFT-
guided group harboring HPRoC were mostly switched over
to prasugrel. Importantly, prasugrel therapy was not a pre-
dictor of lower mortality in the overall cohort, but it was
associated with a reduction in all-cause death only in pa-
tients with HPRoC. These findings may explain why PFT-
guided P2Y12-inhibitor treatment selection, but not prasugrel
therapy, prevailed as an independent predictor of improved
survival in the multivariate analysis. These results were con-
firmed both in the overall and in the PS-matched cohorts.
Prasugrel and ticagrelor showed a significant reduction in
the risk of ischemic end points in AMI patients.13,14 However,
both potent P2Y12 inhibitors were associated with a higher
risk of major bleeding, and in case of prasugrel, no appar-
ent benefit in patients over 75 years of age or with low body
Figure 1. Flowchart of patient selection. TIA = transient ischemic attack.
Figure 2. Results of the platelet function tests (A) and P2Y12 antagonist therapy in the platelet function test results defined groups of the propensity-adjusted
sample (B). ADP = adenosine diphosphate; AUC = area under the curve.
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Figure 3. Kaplan–Meier curves of survival comparing platelet function test–guided versus unguided treated myocardial infarction cases assessed in the PS-
adjusted sample and in the whole cohort.
Table 2
Clinical outcomes of platelet function test guided versus unguided patients
A. Propensity matched cohort (n = 2104)
Nr. of patients (%) Hazard Ratio [95%
Confidence interval]
Platelet function guided
treatment (n = 1052)
Unguided treatment
(n = 1052)
Death from any cause 75 (7.1 %) 125 (11.9 %) 0.57 [0.43–0.77]***
Death from cardiovascular causes 66 (6.3 %) 104 (9.9 %) 0.61 [0.45–0.83]**
Repeated myocardial infarction 29 (2.8 %) 20 (1.9 %) 1.38 [0.78–2.44]
Stroke 8 (0.8 %) 8 (0.8 %) 0.95 [0.36–2.54]
Major adverse cardiac events (cardiovascular death, myocardial infarction, or stroke) 97 (9.2 %) 126 (12.0 %) 0.74 [0.57–0.96]*
Transfusion 74 (7.0 %) 67 (6.4 %) 1.01 [0.73–1.41]
B. Unmatched cohort (n = 3974)
Platelet function guided
treatment (n = 2901)
Unguided treatment
(n = 1073)
Hazard Ratio [95%
Confidence interval]
Death from any cause 163 (5.6 %) 129 (12.0 %) 0.44 [0.35–0.56]***
Death from cardiovascular causes 139 (4.8 %) 107 (10.0 %) 0.45 [0.35–0.58]***
Repeated myocardial infarction 71 (2.4 %) 20 (1.9 %) 1.22 [0.74–2.01]
Stroke 23 (0.8 %) 8 (0.7 %) 0.99 [0.44–2.21]
Major adverse cardiac events (cardiovascular death, myocardial infarction, or stroke) 218 (7.5 %) 129 (12.0 %) 0.59 [0.47–0.73]***
Transfusion 131 (4.5 %) 70 (6.5 %) 1.03 [0.92–1.64]
Data from Cox-regression analyses are presented as hazard ratio [95% Confidence interval], asterisks marks comparisons with p value * < 0.05, ** <0.01,
and *** <0.001. Patients could have had more than one type of end point.
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Figure 4. Kaplan–Meier curves depicting the outcome of patients with prasugrel or clopidogrel treatment in the strata of unguided treatment, HPRoC or no
HPRoC. (A) Propensity-matched cohort (n = 2,104). (B) Unmatched cohort (n = 3,974).
Figure 5. Subgroup analyses within the propensity-matched cohort according to platelet function test results. Forest plots depict HR and 95% CI of 1-year
mortality according to the used P2Y12 blocker. Pinteraction = 0.63.
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weight was shown. These, together with the higher-treatment
costs, still limit the clinical uptake of newer P2Y12-receptor
inhibitors in the routine.3,15,16 Tailoring treatments based on
biomarkers and genes is an emerging field in multiple areas
of medicine. Studies of genetic testing may identify sub-
jects with characteristics that may affect pharmacodynamic
effects of clopidogrel, whereas theoretically, PFT could be
useful in measuring the achieved platelet inhibition and guide
the choice of the P2Y12 inhibitor to reach an optimal range
of platelet inhibition.17,18 Genetic polymorphisms targeted by
the tests may affect clopidogrel absorption, metabolism that
has minor or no influence on new-generation P2Y12 block-
ers’ effects. In contrast, PFT is more subject to methodologic
difficulties but reflect an actual state of platelet inhibition.12,17–19
Importantly, 3 available randomized controlled trials failed
to support the use of PFT to adjust treatment in patients un-
dergoing coronary intervention.2,20–22 Consequently the 2017
ESC–focused update document on dual antiplatelet therapy
in coronary artery disease does not recommend the routine
PFT to adjust antiplatelet therapy before or after elective
stenting.2
From 2011, Hungarian health insurer reimbursed prasugrel
for acute coronary syndrome patients undergoing coronary
intervention who had either diabetes or AMI, but only in cases
when PFT verified the clopidogrel nonresponder status. The
reimbursement is independent from the genetic characteris-
tics. This regulation practically acts as a prasugrel prescribing
policy due to the high costs of unreimbursed prasugrel for
patients and resulted in a high frequency of PFT screening.
Our data are in line with the results of the GRAVITAS trial
as we did not detect a significant clinical difference between
high-dose and standard-dose clopidogrel in case of HPRoC.20
The ARCTIC study randomized patients to PFT-guided and
unguided strategies, similar to our design. However, cases with
ST segment elevation—similar to the GRAVITAS trial—
were excluded. Importantly, interventions to overcome low
responsiveness included complex pharmacologic strategies,
but switching over to prasugrel was rarely used (9%).21 In the
ANTARCTIC acute coronary patients over 75 years re-
ceived either 5 mg of prasugrel or PFT-guided therapy including
5 or 10 mg of prasugrel or 75 mg of clopidogrel according to
the results of VerifyNow testing. Importantly, the ANTARC-
TIC study was mostly a step-down trial with 40% of the patients
switched back to clopidogrel and only 4% scaled up to 10 mg
of prasugrel.22 Similar to ANTARCTIC, the recently pub-
lished TROPICAL ACS trial also used a PFT-guided de-
escalation approach based on the Multiplate (Roche Diagnostics
GmbH) assay. In the trial, patients with AMI were random-
ized to universal prasugrel treatment or PFT-guided early de-
escalation from prasugrel to clopidogrel if no HPRoC was
detected. The TROPICAL ACS study is the first to support
that a PFT-guided strategy is equally safe and effective as the
guideline-recommended strategy.23 Our registry recruited a
high-risk, routine AMI cohort with patients including 55%
ST-segment elevation and 45% AMI without ST-segment el-
evation applying 70% switchover rate to prasugrel. In this high-
risk registry cohort, we could analyze predictors of mortality,
resulting in strong statistical associations.
Although in the trial leading to the approval of prasugrel
previous exposure to clopidogrel was an exclusion criterion
for study entry, we have increasing amount of data regard-
ing switching between antiplatelets.3,13,24 In fact, switching
occurs frequently in clinical practice for various reasons. Dif-
ferences in pharmacology due to binding site, half-life, and
speed of onset and offset of action differences may incite drug
interactions. Studies have not raised any major concerns as-
sociated with the clopidogrel–prasugrel switch but consistently
showed a decreased level of residual platelet reactivity.24 The
most relevant studies were the SWAP and the TRIPLET trials
that included acute cases with results raising no concerns re-
garding prasugrel administration in clopidogrel-treated
patients.25,26 The recently published ESC–focused update on
dual antiplatelet therapy in coronary artery disease also pro-
vides switching algorithms in case of clinical need.2
Table 3
Clinical, procedural, and pharmacological predictors of all-cause death at one year
Variable Univariate Cox proportional
hazard model
p-value Multivariate Cox proportional
hazard model
p-value
Hazard Ratio [95%
Confidence Interval]
Hazard Ratio [95%
Confidence Interval]
History of peripheral artery disease 2.79 [2.01–3.88] <0.001 2.97 [2.11–4.18] 0.001
Smoker 1.59 [1.17–2.17] 0.003 1.74 [1.27–2.38] 0.001
Age (per 10 yrs increase) 1.56 [1.34–1.82] <0.001 1.62 [1.38–1.90] <0.001
Heart rate (per 10/min increase) 1.26 [1.18–1.34] <0.001 1.25 [1.17–1.33] <0.001
Systolic blood pressure (per 10 Hgmm increase) 0.85 [0.80–0.90] <0.001 0.83 [0.78–0.88] <0.001
Platelet function test guidance 0.57 [0.43–0.77] <0.001 0.52 [0.39–0.69] <0.001
Hypertension 1.24 [0.93–1.66] 0.149 1.56 [1.14–2.10] 0.005
Diabetes 1.57 [1.18–2.08] 0.002 1.55 [1.11–2.03] 0.005
Culprit artery: left main coronary 3.01 [1.80–5.02] <0.001 2.01 [1.18–3.39] <0.009
Diastolic blood pressure (per 10 mm Hg increase) 0.98 [0.93–1.03] 0.422 0.94 [0.88–1.00] 0.036
Male gender 0.92 [067-1.22] 0.545
Hyperlipidaemia 0.83 [0.39–1.76] 0.626
Prior myocardial infarction 0.98 [0.72–1.35] 0.910
Prior of coronary bypass operation 1.09 [0.27–4.39] 0.905
ST segment elevation myocardial infarction 1.27 [0.96–1.68] 0.102
Prasugrel treatment 0.65 [0.38–1.11] 0.116
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Our data originate from a nationwide, multicenter screen-
ing system using uniform whole-blood impedance
aggregometry that strengthens the results; however, there
remain important limitations to acknowledge. First, we have
no information on how the individual decisions based on
patient characteristics and logistics were made. Indeed, pa-
tients in whom PFT was performed differed in several features
from the unguided patients. Although the exclusion of cases
with absolute and relative contraindications to prasugrel and
PS matching balanced significant differences observed between
the PFT-guided and unguided groups, other, potentially un-
controlled variables may also exist that potentially influenced
the choice of treatment. Keeping this limitation in mind, the
statistically robust difference (p <0.001) in the propensity-
matched cohorts confirms the validity of the results. Second,
we collected information regarding the clinical events using
a payer’s database that may not have been used as standard-
ized definitions for a bleeding event, stent thrombosis, and
myocardial infarction as usual in clinical trials. Further-
more, because ticagrelor was not available at the time of the
study, it may restrict its generalizability. Third, in our pro-
spective database we lack reliable information regarding the
drug-compliance and later changes on medications, and we
confined our analyses to intention-to-treat groups based on
the discharge summaries of the index events.
Conclusions
Based on the results from an all-comer, high-risk cohort
of a nationwide registry of AMI patients, cases with PFT-
guided selection of P2Y12-inhibitor therapy had lower mortality
in contrast to lack of PFT guidance and clinical decision
making. Although the PFT-guided group showed a higher fre-
quency of switchover to prasugrel, allocation to prasugrel
versus clopidogrel did not reduce mortality in the overall
cohort. In contrast, prasugrel treatment significantly im-
proved survival in patients with HPRoC compared with
standard- and high-dose clopidogrel.
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